FDA schedules November panel for J&J's TB product

FDA's Anti-Infective Drugs Advisory Committee will meet on Nov. 28 to discuss an NDA from Johnson & Johnson (NYSE:JNJ) for bedaquiline ( TMC207) to treat multi-drug-resistant tuberculosis. The applica...